Phospho-AURKB (Y12) Antibody

What is Aurora Kinase B and why is phosphorylation at Y12 significant?

Aurora Kinase B (AURKB) is a mitotic serine/threonine protein kinase that belongs to the aurora kinase family along with aurora kinase A (AURKA) and aurora kinase C (AURKC). It functions as a key member of the chromosomal passenger protein complex and plays essential roles in cell cycle progression, particularly during mitosis . The phosphorylation at tyrosine 12 (Y12) represents a specific post-translational modification that potentially modulates AURKB's enzymatic activity, protein-protein interactions, and subcellular localization. Studying this specific phosphorylation site helps researchers understand the complex regulatory mechanisms controlling AURKB function in normal and pathological conditions.

How does AURKB function in normal cell division?

AURKB plays critical roles throughout mitosis and cytokinesis. During cell division, AURKB phosphorylates histone H3 on Ser10, which is essential for chromosome condensation and segregation . This phosphorylation activity contributes to proper chromosome alignment at the metaphase plate. Additionally, AURKB ensures accurate chromosome segregation by detecting and correcting improper kinetochore-microtubule attachments. During cytokinesis, AURKB localizes to the midbody and participates in abscission, the final step of cell division. The precise timing and localization of AURKB activity, potentially regulated by phosphorylation at sites like Y12, are crucial for error-free cell division.

What experimental methods typically utilize Phospho-AURKB (Y12) antibodies?

Researchers typically employ Phospho-AURKB (Y12) antibodies in multiple experimental approaches:

• Western blotting: For quantitative assessment of phosphorylation levels across different experimental conditions

• Immunofluorescence microscopy: To visualize subcellular localization of phosphorylated AURKB during various cell cycle stages

• Immunoprecipitation: To isolate phosphorylated AURKB and identify interacting partners

• Chromatin immunoprecipitation (ChIP): To analyze AURKB association with chromatin

• Flow cytometry: For quantitative single-cell analysis of phosphorylation in heterogeneous populations

• Immunohistochemistry: To examine phosphorylation status in tissue sections from clinical samples

Each application requires specific optimization protocols to ensure antibody specificity and sensitivity for the phosphorylated epitope.

How is AURKB dysregulation linked to cancer development?

Deregulation of AURKB is observed in several tumor types and its overexpression is frequently linked to tumor cell invasion, metastasis, and drug resistance . Elevated AURKB expression has been associated with increased phosphorylation of histone H3 on Ser10 and aneuploidy, as demonstrated in Chinese hamster embryo cells . The function of AURKB in cellular transformation has been confirmed in vivo through mouse models, and induced AURKB expression is linked to tumorigenesis mediated by H-Ras . These findings highlight why AURKB has emerged as an important drug target, with numerous small molecule inhibitors being developed to specifically target AURKB function in various tumors. Understanding the phosphorylation status at sites like Y12 may provide insights into AURKB activation mechanisms in cancer.

How does Y12 phosphorylation of AURKB affect its interaction with other chromosomal passenger complex (CPC) proteins?

Y12 phosphorylation potentially modulates AURKB's interaction with other CPC components (Survivin, Borealin, and INCENP). Methodologically, researchers can investigate this by performing co-immunoprecipitation experiments using Phospho-AURKB (Y12) antibodies compared to total AURKB antibodies. Proximity ligation assays (PLA) can detect changes in protein-protein interactions in situ. Additionally, FRET-based approaches can measure interaction dynamics in living cells. When analyzing data, researchers should compare interaction patterns throughout the cell cycle and across different experimental conditions to determine if Y12 phosphorylation affects CPC assembly, stability, or localization to various subcellular structures during mitosis.

What is the relationship between AURKB Y12 phosphorylation and response to aurora kinase inhibitors?

AURKB inhibitors like Barasertib (AZD1152) have shown promising results in clinical trials, particularly in acute myeloid leukemia with a response rate of 19% in Japanese patients . To methodically investigate whether Y12 phosphorylation status affects inhibitor efficacy, researchers should:

• Treat cells with various AURKB inhibitors at different concentrations

• Assess Y12 phosphorylation status before and after treatment

• Correlate phosphorylation changes with markers of inhibitor efficacy (polyploidy, apoptosis)

• Compare responses across cell lines with different baseline Y12 phosphorylation levels

• Generate phosphomimetic (Y12D/E) or phospho-deficient (Y12F) AURKB mutants to directly test the impact on inhibitor sensitivity

This systematic approach helps determine whether Y12 phosphorylation serves as a biomarker for treatment response or contributes to resistance mechanisms.

How does the crosstalk between AURKB Y12 phosphorylation and other post-translational modifications affect kinase function?

AURKB undergoes multiple post-translational modifications beyond Y12 phosphorylation. To methodically investigate crosstalk, researchers should employ mass spectrometry-based phosphoproteomics to map all modifications simultaneously. Sequential immunoprecipitation with phospho-specific antibodies can identify protein populations with multiple modifications. In vitro kinase assays using purified AURKB with different modification patterns help determine functional consequences. Researchers should systematically introduce mutations that prevent specific modifications and assess how this affects other sites, particularly Y12 phosphorylation. Integration of these approaches provides insights into the complex post-translational regulation of AURKB activity.

What role does Phospho-AURKB (Y12) play in therapy resistance mechanisms?

To methodically investigate Y12 phosphorylation in therapy resistance, researchers should:

• Generate resistant cell lines through long-term exposure to AURKB inhibitors or other cancer therapies

• Compare Y12 phosphorylation levels between parental and resistant lines

• Manipulate Y12 phosphorylation (through phosphatase treatment or mutagenesis) and assess impact on drug sensitivity

• Identify kinases responsible for Y12 phosphorylation as potential co-targets

• Analyze clinical samples from patients before treatment and after developing resistance

This systematic approach may reveal whether altered Y12 phosphorylation contributes to resistance mechanisms and whether it could serve as a biomarker for predicting treatment outcomes.

What are the optimal conditions for detecting Phospho-AURKB (Y12) by Western blotting?

For optimal Western blot detection of Phospho-AURKB (Y12):

• Sample preparation:

  • Add phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) immediately during lysis

  • Maintain samples at 4°C throughout processing

  • Avoid repeated freeze-thaw cycles

• Gel electrophoresis and transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Transfer to PVDF membranes (preferred over nitrocellulose for phospho-epitopes)

  • Use wet transfer systems at lower voltage for longer duration

• Antibody incubation:

  • Block with 5% BSA in TBST (avoid milk, which contains phosphatases)

  • Dilute antibody in 5% BSA/TBST (typically 1:500-1:2000)

  • Incubate primary antibody overnight at 4°C with gentle agitation

• Controls:

  • Include lambda phosphatase-treated lysates as negative controls

  • Use mitotic cell lysates as positive controls

  • Include total AURKB antibody detection for normalization

This methodical approach ensures specific and sensitive detection of the phosphorylated epitope.

What cell synchronization methods are most effective for studying AURKB Y12 phosphorylation during mitosis?

To systematically study Y12 phosphorylation throughout mitosis:

Each collected sample should be analyzed for Y12 phosphorylation by Western blotting and immunofluorescence, along with cell cycle markers to confirm synchronization efficiency.

How can I validate the specificity of my Phospho-AURKB (Y12) antibody?

A robust validation approach includes:

• Phosphatase treatment:

  • Treat cell lysates with lambda phosphatase before Western blotting

  • Signal should disappear or significantly decrease

• Competitive blocking with phosphopeptides:

  • Pre-incubate antibody with phosphorylated and non-phosphorylated Y12 peptides

  • Only phosphopeptide should block specific signal

• Genetic approaches:

  • Use CRISPR/Cas9 to generate Y12F mutant (phospho-deficient)

  • Compare with wild-type and Y12E (phosphomimetic) controls

• Immunodepletion:

  • Sequential immunoprecipitation with the phospho-antibody

  • Analyze depleted lysate for remaining signal

• Mass spectrometry confirmation:

  • Immunoprecipitate with phospho-antibody

  • Confirm presence of phosphorylated Y12 by mass spectrometry

This comprehensive validation ensures antibody specificity and reliability of subsequent experimental data.

What factors affect the detection of Phospho-AURKB (Y12) in immunofluorescence microscopy?

For optimal immunofluorescence detection:

• Fixation methods:

  • Test both paraformaldehyde (4%, 10 min) and methanol (-20°C, 10 min)

  • Phospho-epitopes often better preserved with methanol fixation

• Permeabilization:

  • 0.2% Triton X-100 for PFA-fixed cells

  • Not required for methanol-fixed cells

• Blocking conditions:

  • 5% BSA in PBS for 60 minutes at room temperature

  • Add 5% normal serum from secondary antibody host species

• Antibody dilution:

  • Titrate antibody (typically 1:50-1:500)

  • Incubate overnight at 4°C in humid chamber

• Signal enhancement:

  • Consider tyramide signal amplification for weak signals

  • Use high-sensitivity detection systems

• Co-staining markers:

  • Include α-tubulin to visualize mitotic spindles

  • Use CREST antibody for centromeres/kinetochores

  • DAPI for DNA visualization

This methodical approach helps obtain clear subcellular localization of phosphorylated AURKB during different mitotic stages.

How should Phospho-AURKB (Y12) signals be quantified in relation to total AURKB levels?

For accurate quantification and interpretation:

• Western blot analysis:

  • Always probe for total AURKB on the same blot after stripping

  • Calculate phospho-to-total AURKB ratio for each sample

  • Use fluorescent secondary antibodies for wider linear range

  • Include standard curves with known quantities of recombinant proteins

• Immunofluorescence quantification:

  • Perform dual staining with phospho-specific and total AURKB antibodies

  • Use different fluorophores to distinguish signals

  • Calculate intensity ratios at specific subcellular locations

  • Analyze >100 cells per condition for statistical robustness

• Normalization considerations:

  • Account for cell cycle distribution in asynchronous populations

  • For cell populations with different AURKB expression levels, first normalize phospho-signal to total AURKB, then compare between conditions

This approach provides more meaningful data about the proportion of AURKB that is phosphorylated rather than absolute signal intensity alone.

How can contradictory results between different detection methods for Phospho-AURKB (Y12) be reconciled?

When facing contradictory results:

• Systematically evaluate technical factors:

  • Different antibody lots or clones may have varying specificities

  • Each method preserves epitopes differently (Western blot: denatured; IF: native conformation)

  • Fixation methods can affect epitope accessibility

• Consider biological explanations:

  • Subcellular compartmentalization may affect detection

  • Phosphorylation may be transient or context-dependent

  • Other modifications might mask the Y12 epitope

• Resolution strategies:

  • Employ orthogonal detection methods (mass spectrometry)

  • Use genetic approaches (Y12F/E mutations) to validate findings

  • Perform time-course experiments with higher temporal resolution

  • Isolate subcellular fractions for separate analysis

By systematically investigating both technical and biological factors, researchers can resolve apparently contradictory results and gain deeper insights into the dynamics of Y12 phosphorylation.

What statistical approaches are most appropriate for analyzing Phospho-AURKB (Y12) data across experimental conditions?

For robust statistical analysis:

• For Western blot densitometry:

  • Perform at least three independent biological replicates

  • Use paired t-tests when comparing treated vs. control from same experiment

  • Apply ANOVA with post-hoc tests for multiple conditions

  • Consider non-parametric tests if normality cannot be established

• For immunofluorescence intensity:

  • Use mixed-effects models to account for cell-to-cell variability

  • Include experiment as a random effect to control for batch variation

  • Transform data if necessary to meet normality assumptions

• For correlation analyses:

  • Calculate Pearson's or Spearman's correlation coefficients between phosphorylation and functional outcomes

  • Use regression models to identify predictive relationships

• For high-content data:

  • Consider dimensionality reduction techniques (PCA)

  • Apply machine learning approaches for pattern recognition

How does Phospho-AURKB (Y12) status correlate with sensitivity to different AURKB inhibitors?

Researchers investigating correlations between Y12 phosphorylation and inhibitor sensitivity should:

• Profile a panel of cancer cell lines for:

  • Baseline Y12 phosphorylation levels

  • Response to various AURKB inhibitors (IC50 values)

  • Changes in Y12 phosphorylation following inhibitor treatment

• Compare responses across inhibitor classes:

  • AURKB-specific inhibitors (e.g., Barasertib)

  • Pan-Aurora inhibitors (e.g., AT9283, CYC116)

  • ATP-competitive vs. allosteric inhibitors

Below is a table summarizing key AURKB inhibitors from clinical development:

This systematic approach helps determine whether Y12 phosphorylation could serve as a biomarker for treatment selection.

How can Phospho-AURKB (Y12) antibodies be used in patient-derived samples to guide therapy decisions?

For clinical applications:

• Tissue microarray analysis:

  • Quantify Y12 phosphorylation in tumor samples by immunohistochemistry

  • Correlate with clinical outcomes and treatment responses

  • Establish scoring systems based on staining intensity and distribution

• Ex vivo drug sensitivity testing:

  • Treat patient-derived cells with AURKB inhibitors

  • Monitor changes in Y12 phosphorylation

  • Correlate with apoptotic response and growth inhibition

• Liquid biopsy applications:

  • Detect Phospho-AURKB (Y12) in circulating tumor cells

  • Monitor treatment response longitudinally

  • Identify emergence of resistance

• Combination therapy strategies:

  • Test whether Y12 phosphorylation status predicts synergy with other targeted agents

  • Develop rational combination approaches based on phosphorylation patterns

This translational approach bridges laboratory findings with clinical applications, potentially enabling more personalized treatment strategies.

What are the methodological considerations for developing Phospho-AURKB (Y12) as a biomarker in clinical trials?

For biomarker development:

• Analytical validation:

  • Establish reproducibility across different laboratories

  • Determine antibody specificity in clinical specimens

  • Develop standard operating procedures for sample handling

• Clinical validation:

  • Define threshold values for "positive" vs "negative" status

  • Evaluate prognostic value in retrospective cohorts

  • Assess predictive value for response to AURKB inhibitors

• Standardization approaches:

  • Include calibration controls in each assay

  • Develop quantitative assays (ELISA, MSD platforms)

  • Implement digital pathology for objective quantification

• Practical considerations:

  • Evaluate effects of pre-analytical variables (fixation time, storage)

  • Determine stability of the phospho-epitope

  • Assess feasibility in commonly available sample types

This systematic approach ensures that Phospho-AURKB (Y12) detection can be reliably implemented as a biomarker in clinical trials testing AURKB inhibitors or other cancer therapies.